Cargando…

A Randomized, Active-Controlled, 52-Week Study of Hyaluronic Acid Fillers for Anteromedial Malar Region Augmentation

BACKGROUND: Hyaluronic acid (HA) fillers for volume augmentation in the anteromedial malar region of Asians have been popular for many years. However, studies on their long-term effectiveness are lacking. This study aimed to evaluate the effectiveness and safety of HA fillers injected into the anter...

Descripción completa

Detalles Bibliográficos
Autores principales: Huh, Chang-Hun, Eom, Yunae, Yang, So Dam, Shin, Jung Won, Seo, Kyle Koo-il
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7159933/
https://www.ncbi.nlm.nih.gov/pubmed/32309093
http://dx.doi.org/10.1097/GOX.0000000000002648
_version_ 1783522667038507008
author Huh, Chang-Hun
Eom, Yunae
Yang, So Dam
Shin, Jung Won
Seo, Kyle Koo-il
author_facet Huh, Chang-Hun
Eom, Yunae
Yang, So Dam
Shin, Jung Won
Seo, Kyle Koo-il
author_sort Huh, Chang-Hun
collection PubMed
description BACKGROUND: Hyaluronic acid (HA) fillers for volume augmentation in the anteromedial malar region of Asians have been popular for many years. However, studies on their long-term effectiveness are lacking. This study aimed to evaluate the effectiveness and safety of HA fillers injected into the anteromedial malar region for volume augmentation for up to 52 weeks. METHODS: Each anteromedial malar region of the subjects was treated with YVOIRE Contour (YVO(C)) in one side and Restylane Sub-Q (RES(S)) in the other and followed up at weeks 2, 14, 26, and 52. The volume using the mid-face aesthetic scale (MFAS) ranging from 0 (full) to 4 (very severely sunken) and the subject’s satisfaction and adverse events were evaluated. RESULTS: Total 83 subjects were randomized and treated with YVO(C) and RES(S). The LS means (standard error) of MFAS score in the YVO(C) and RES(S) groups were both 2.56 (0.05) at baseline, 1.32 (0.07) and 1.39 (0.07) at week 26, and 1.84 (0.10) and 1.89 (0.10) at week 52, respectively. The difference in the LS mean of MFAS score between the groups at week 26 was 0.07 (95% confidence interval, 0.01–0.12), showing the non-inferiority of YVO(C) to RES(S). About 70% of subjects were still satisfied with the results at week 52. No specific safety concern was detected. CONCLUSIONS: The HA fillers injected for the anteromedial malar augmentation maintained the volume well for up to 52 weeks. Additionally, both YVO(C) and RES(S) show similar effectiveness and safety profiles.
format Online
Article
Text
id pubmed-7159933
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-71599332020-04-17 A Randomized, Active-Controlled, 52-Week Study of Hyaluronic Acid Fillers for Anteromedial Malar Region Augmentation Huh, Chang-Hun Eom, Yunae Yang, So Dam Shin, Jung Won Seo, Kyle Koo-il Plast Reconstr Surg Glob Open Original Article BACKGROUND: Hyaluronic acid (HA) fillers for volume augmentation in the anteromedial malar region of Asians have been popular for many years. However, studies on their long-term effectiveness are lacking. This study aimed to evaluate the effectiveness and safety of HA fillers injected into the anteromedial malar region for volume augmentation for up to 52 weeks. METHODS: Each anteromedial malar region of the subjects was treated with YVOIRE Contour (YVO(C)) in one side and Restylane Sub-Q (RES(S)) in the other and followed up at weeks 2, 14, 26, and 52. The volume using the mid-face aesthetic scale (MFAS) ranging from 0 (full) to 4 (very severely sunken) and the subject’s satisfaction and adverse events were evaluated. RESULTS: Total 83 subjects were randomized and treated with YVO(C) and RES(S). The LS means (standard error) of MFAS score in the YVO(C) and RES(S) groups were both 2.56 (0.05) at baseline, 1.32 (0.07) and 1.39 (0.07) at week 26, and 1.84 (0.10) and 1.89 (0.10) at week 52, respectively. The difference in the LS mean of MFAS score between the groups at week 26 was 0.07 (95% confidence interval, 0.01–0.12), showing the non-inferiority of YVO(C) to RES(S). About 70% of subjects were still satisfied with the results at week 52. No specific safety concern was detected. CONCLUSIONS: The HA fillers injected for the anteromedial malar augmentation maintained the volume well for up to 52 weeks. Additionally, both YVO(C) and RES(S) show similar effectiveness and safety profiles. Wolters Kluwer Health 2020-02-26 /pmc/articles/PMC7159933/ /pubmed/32309093 http://dx.doi.org/10.1097/GOX.0000000000002648 Text en Copyright © 2020 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of The American Society of Plastic Surgeons. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (http://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
spellingShingle Original Article
Huh, Chang-Hun
Eom, Yunae
Yang, So Dam
Shin, Jung Won
Seo, Kyle Koo-il
A Randomized, Active-Controlled, 52-Week Study of Hyaluronic Acid Fillers for Anteromedial Malar Region Augmentation
title A Randomized, Active-Controlled, 52-Week Study of Hyaluronic Acid Fillers for Anteromedial Malar Region Augmentation
title_full A Randomized, Active-Controlled, 52-Week Study of Hyaluronic Acid Fillers for Anteromedial Malar Region Augmentation
title_fullStr A Randomized, Active-Controlled, 52-Week Study of Hyaluronic Acid Fillers for Anteromedial Malar Region Augmentation
title_full_unstemmed A Randomized, Active-Controlled, 52-Week Study of Hyaluronic Acid Fillers for Anteromedial Malar Region Augmentation
title_short A Randomized, Active-Controlled, 52-Week Study of Hyaluronic Acid Fillers for Anteromedial Malar Region Augmentation
title_sort randomized, active-controlled, 52-week study of hyaluronic acid fillers for anteromedial malar region augmentation
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7159933/
https://www.ncbi.nlm.nih.gov/pubmed/32309093
http://dx.doi.org/10.1097/GOX.0000000000002648
work_keys_str_mv AT huhchanghun arandomizedactivecontrolled52weekstudyofhyaluronicacidfillersforanteromedialmalarregionaugmentation
AT eomyunae arandomizedactivecontrolled52weekstudyofhyaluronicacidfillersforanteromedialmalarregionaugmentation
AT yangsodam arandomizedactivecontrolled52weekstudyofhyaluronicacidfillersforanteromedialmalarregionaugmentation
AT shinjungwon arandomizedactivecontrolled52weekstudyofhyaluronicacidfillersforanteromedialmalarregionaugmentation
AT seokylekooil arandomizedactivecontrolled52weekstudyofhyaluronicacidfillersforanteromedialmalarregionaugmentation
AT huhchanghun randomizedactivecontrolled52weekstudyofhyaluronicacidfillersforanteromedialmalarregionaugmentation
AT eomyunae randomizedactivecontrolled52weekstudyofhyaluronicacidfillersforanteromedialmalarregionaugmentation
AT yangsodam randomizedactivecontrolled52weekstudyofhyaluronicacidfillersforanteromedialmalarregionaugmentation
AT shinjungwon randomizedactivecontrolled52weekstudyofhyaluronicacidfillersforanteromedialmalarregionaugmentation
AT seokylekooil randomizedactivecontrolled52weekstudyofhyaluronicacidfillersforanteromedialmalarregionaugmentation